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Tbjective: Renal cell carcinomas often form venous thrombi that extend into the
ena cava. Frequently, cardiovascular consultation is necessary for complete sur-
ical excision. We sought to investigate the risk factors, surgical techniques, and
utcomes of patients treated for renal cell carcinoma with venous extension.
ethods: We reviewed the records of 46 consecutive patients who underwent
urgical management of renal cell carcinoma with venous extension between 1991
nd 2005. Data on patient history, staging, surgical techniques, morbidity, and
urvival were analyzed.
esults: There were 29 men and 17 women with a mean age of 60.2  12.0 years.
wenty-five (54%) procedures were completed with cardiovascular assistance.
ephrectomy was performed in 44 (96%) cases. Three (7%) patients underwent
ight heart venovenous bypass, and 2 (5%) patients underwent cardiopulmonary
ypass with circulatory arrest. Fourteen (32%) patients had perioperative compli-
ations, including 1 (2%) perioperative death. Patients who required cardiovascular
rocedures (inferior vena cava clamping, right heart venovenous bypass, and car-
iopulmonary bypass with circulatory arrest) had higher risks of perioperative
omplications (P  .02). The 1-, 2-, and 5-year overall survival rates were 78%,
9%, and 56%.
onclusions: This large series demonstrates that aggressive treatment of renal cell
arcinoma with venous thrombus provides favorable outcomes. Our 5-year survival
s among the highest of recent reviews, and our perioperative morbidity and mortality
ates are comparable with those of other series. Tumors that require cardiovascular
rocedures are associated with increased complications when compared with radical
ephrectomy and thrombectomy alone. Nevertheless, this aggressive treatment
pproach offers encouraging patient survival.
enal cell carcinoma (RCC) is the most common renal neoplasm. Cancers of
the kidney and renal pelvis are 12th among the leading causes of cancer
deaths, accounting for 36,160 new diagnoses and 12,660 deaths in the
nited States in 2005.1
Successful modern radical nephrectomy for the treatment of RCC was first
eported in 1963. It involved removal of Gerota’s fascia and its contents, including
he kidney, adrenal gland, and perinephric adipose tissue.2 Today, the frequent us
f abdominal imaging results in earlier diagnosis of smaller tumors that are fre-
uently amenable to nephron-sparing surgery by means of open or laparoscopic
echniques.3,4 For large tumors, laparoscopic radical nephrectomy and open ra
ephrectomy are both considered the standard of care.5
he Journal of Thoracic and Cardiovascular Surgery ● Volume 131, Number 6 1289
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1
A
CDDespite improvements in radiographic imaging and sur-
ical techniques, RCC remains a technically challenging
umor to completely excise. This is attributed to its unique
endency for early extension into the renal veins and inferior
ena cava (IVC).6 Tumor thrombus is present in up to 2
f patients presenting with RCC.7-12 The cephalad exten
an range from the renal vein or IVC to the right atrium or
roximal pulmonary artery.13 This extension dramatically
ncreases the technical difficulty of safely removing the
rimary renal tumor and extracting the entire venous tumor
hrombus.
Although an experienced urologist traditionally performs
adical nephrectomy, occasionally multimodal techniques,
uch as liver mobilization, control of the vena cava, ster-
otomy, right heart venovenous bypass, and cardiopulmo-
ary bypass with circulatory arrest, are necessary for safe
nd effective venous tumor thrombus extraction.14 This
ultimodal approach often involves cardiothoracic sur-
eons who have the benefit of extensive experience in the
urgical management of the vena cava, heart, and thorax.
Although RCC with tumor thrombus presents as a chal-
enging procedure for the surgeon, removal is the treatment
f choice and results in increased disease-free survival.15 In
n effort to further improve the treatment of this population,
e analyzed patients who underwent surgical management
f RCC with venous extension to assess risk factors, surgi-
al techniques, and outcomes of their care.
atients and Methods
e obtained institutional review board approval and retrospec-
ively reviewed the medical records of 46 consecutive patients who
resented with RCC with extension into the renal vein, IVC, or
ight atrium to the hospitals of the University of Texas Southwest-
rn Medical Center at Dallas between April 1991 and April 2005.
ata on patient demographics and history, clinical staging, surgi-
al techniques, histopathologic staging, and perioperative morbid-
ty and mortality were collected from medical records. Survival
ata were collected from follow-up records and office charts.
Several imaging modalities were used in the initial and follow-up
are of these patients. The tumors were clinically staged by using
bdominal and chest computed tomographic scans with other imag-
ng techniques, including chest radiography. Magnetic resonance
maging was used in evaluation of the level of thrombus. Bone
cans were used selectively in patients with large tumors or in-
reased alkaline phosphatase levels. Additionally, positron emis-
ion tomography was used postoperatively for assessment of re-
idual masses and restaging in follow-up care.
Tumor thrombus extension was classified according to 4 levels:
Abbreviations and Acronyms
IVC  inferior vena cava
RCC renal cell carcinomaevel I, extension into the renal vein; level II, extension into the p
290 The Journal of Thoracic and Cardiovascular Surgery ● Junnfrahepatic IVC; level III, IVC extension to the level of hepatic
eins but below the diaphragm; and level IV, IVC extension above
he diaphragm and into the right atrium or beyond. Bilateral tumors
ere classified according to the extent of the larger tumor. Patho-
ogic and histologic stages were assigned according to the 2002
NM staging system and Fuhrman classification, respectively.16,17
Preoperative renal artery alcohol angioembolization was per-
ormed to facilitate arterial vascular control in patients with bulky
umor thrombus, hilar adenopathy, or hypervascularity.
Radical nephrectomy (removal of Gerota’s fascia and its con-
ents, including the kidney, ipsilateral adrenal gland, and perineph-
ic adipose tissue) with removal of the tumor thrombus and re-
ional lymphadenectomy was attempted in all patients.
Cardiovascular procedures, such as IVC clamping, right heart
enovenous bypass, and cardiopulmonary bypass with circulatory
rrest, were available to aid in venous tumor thrombus extraction.
he latter 2 procedures were reserved for patients who could not
olerate IVC clamping or whose tumors extended into the right
trium or beyond.
Perioperative complications within the first 30 days of the
ostoperative period included hemorrhage and coagulopathy, pleu-
al effusion, pneumothorax, prolonged ileus (for 4 days), poor
utritional intake, nausea and vomiting, pancreatitis, deep venous
hrombosis, splenectomy, acute respiratory distress syndrome, neu-
ologic dysfunction, renal failure, pulmonary failure, and death.
Survival time was calculated from the date of the operation to
he date of last contact or date of death. Three patients who were
ost to follow-up were excluded from the survival analysis. The
umulative survival rates were calculated by using Kaplan-Meier
nalysis, and the significance was determined by using the log-
ank test. Categorical variables were analyzed with the 2 and
isher exact tests as appropriate in contingency tables, whereas
he Student t test and Mann-Whitney U test were performed as
ppropriate for comparison of continuous variables. The logistic
egression model was applied for univariate analysis to confirm
etermining factors of complications. Data were expressed as
eans  1 standard deviation unless specified otherwise. All
tatistical analyses were performed with the Statistical Package for
ocial Sciences (SPSS; version 12.0, Chicago, Ill).
esults
linical Features
lthough this study encompasses a 14-year period, 19 (41.3%)
f the patients were treated during the last 2 years of data
ollection. All tumors were classified clinically as either
3b or T3c at the time of diagnosis by using the 2002 TNM
taging system.16 Patient demographics and clinical chara-
eristics are shown in Table 1.
Patients presented asymptomatically or with varying
ymptoms of hematuria, ipsilateral flank pain, weight loss,
ower extremity swelling, change in appetite, feeling of full-
ess, or distended subcutaneous veins. Tumors were local-
zed in the right kidney of 30 (65%) patients and the left
idney of the other 16 (35%) patients. Six (13%) patients
resented with distant metastases, with the most common
ite of metastasis being the lung (n 6). Three (7%) patients
resented with lymphadenopathy. Mean clinical tumor size
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A
CDas 9.7  3.8 cm (range, 4.8-20.0 cm). Eleven (24%) pa-
ients had a level I, 16 (35%) had a level II, 15 (33%) had
level III, and 4 (9%) had a level IV venous tumor throm-
us (Figure 1).
urgical Intervention
f the 46 patients who presented with RCC with tumor
hrombus in this study, 40 (87%) had complete tumor re-
oval, including 39 with radical nephrectomy and tumor
hrombectomy and 1 partial nephrectomy and complete
hrombectomy in a patient with a solitary kidney. Of the
emaining patients, 4 (9%) had successful radical nephrec-
omy with incomplete tumor thrombectomy caused by
xtensive intraoperative hemorrhage (n  1), widespread
ymph node (n  1) or liver (n  1) metastases, or growth
nto the posterior body wall and liver (n  1). Two of these
atients underwent second procedures, and subsequent throm-
ectomy was successful in 1 patient. Nephrectomy was not
erformed in the remaining 2 (4.3%) of the total 46 patients
ecause of intraoperative findings of liver cirrhosis or tumor
xtension into the posterior body wall in 1 patient each.
hese final 2 patients were omitted from further statistical
nalysis.
Thirteen patients underwent preoperative renal artery
lcohol angioembolization. Lymphadenectomy was per-
ormed in 39 (89%) patients, with a mean of 7  6 nodes
range, 1-26 nodes) removed. Ipsilateral adrenalectomy was
erformed in 35 (80%) patients.
Cardiovascular procedures, such as IVC clamping, right
eart venovenous bypass, and cardiopulmonary bypass with
irculatory arrest, were performed in 29 (66%) patients.
ABLE 1. Patient demographics and clinical characteristics
Age*, y 60.2  12.0
Sex
Male 29 (63%)
Female 17 (37%)
Race or ethnic group
White 33 (72%)
Hispanic 7 (15%)
Black 5 (11%)
Other 1 (2%)
Presenting symptoms
Hematuria 29 (63%)
Flank pain 23 (50%)
Weight loss 11 (24%)
Asymptomatic 10 (22%)
Lower extremity swelling 4 (9%)
Change in appetite 2 (4%)
Feeling of fullness 2 (4%)
Distended subcutaneous veins 1 (2%)
ata are presented as the numbers of patients (%) unless otherwise
pecified. *Mean  1 standard deviation.VC clamping was the most common cardiovascular proce- p
The Journal of Thoracicure, performed in 24 patients. Venovenous bypass was
erformed in 3 patients, and cardiopulmonary bypass with
irculatory arrest was performed in 2 patients. See Tab
or surgical descriptions by thrombus level.
evel I Thrombi
leven patients were found to have a thrombus in the renal
ein. No patients in this group received preoperative renal
rtery alcohol angioembolization or cardiovascular consul-
ation during nephrectomy. Negative surgical margins were
eported in 9 (82%) patients. Of the 2 patients with positive
urgical margins, one had a section of metastatic adrenal
land attached to the liver and IVC, and the other had an
dherent lymph node package that could not be entirely
emoved. Three (27%) patients in this group were treated
ostoperatively with immunotherapy.
evel II Thrombi
ifteen patients were operated on with a thrombus extend-
ng into the infrahepatic IVC. Seven patients had preoper-
tive renal artery alcohol angioembolization. IVC clamping
as necessary in 14 patients. A cardiothoracic surgeon as-
isted in 8 (53%) operations. In all but 2 cases (87%), the
urgical margins were negative. One patient had a meta-
tatic adrenal gland adherent to the liver, and the second
igure 1. Magnetic resonance image of a patient with renal
ell carcinoma who presented with a level II venous tumor
hrombus (extension into the infrahepatic inferior vena cava
IVC] ).atient had metastatic adhesions infiltrating the posterior
and Cardiovascular Surgery ● Volume 131, Number 6 1291
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1
A
CDody wall. Successful vena caval thrombectomy was achieved
n all patients (100%). The only perioperative death in this
eries was a 79-year-old man with a history of congestive
eart failure who died on the first postoperative day of intra-
perative hemorrhage resulting from extensive invasion
f the tumor into the posterior body wall and diaphragm,
ollowed by ongoing coagulopathy. One (7%) patient re-
eived preoperative immunotherapy because of extensive
etastatic disease. This patient, along with 3 (27%) others,
eceived immunotherapy postoperatively. One (7%) patient
eceived postoperative chemotherapy.
evel III Thrombi
ourteen patients had a tumor thrombus extending into the
VC behind the liver but below the diaphragm. Of these 14
atients, 5 underwent preoperative renal artery alcohol an-
ioembolization. A cardiothoracic team was present for 13
93%) of the cases in this group. IVC clamping was used for
0 patients. Suprahepatic control of the IVC and control of
he porta hepatis were routinely gained when attempting
umor thrombectomy. In 3 patients who were hemodynam-
cally unstable during the initial cross-clamping of the IVC,
ight heart venovenous bypass was used to assist in removal
f the thrombus. In the majority of patients in this series, the
umor thrombi were free flowing within the lumen of the
VC. At points of adherence, when present, attempts were
ABLE 2. Surgical characteristics by tumor thrombus leve
haracteristic Total Le
atients 44 (100%) 11 (2
ngioembolization 13 (30%)
peration
Radical nephrectomy 43 (98%) 10 (9
Imperative NSS 1 (2%) 1 (9
ncision type
Transverse chevron 35 (80%) 9 (8
Midline 6 (14%)
Flank 2 (5%) 2 (1
Thoracoabdominal 1 (2%)
rocedure duration, min 390 (185-700) 320 (2
VC clamping 24 (55%)
Clamp time, min 31 (3-69)
ight heart venovenous bypass 3 (7%)
Clamp time, min 33 (23-41)
Pump time, min 67 (43-204)
ardiopulmonary bypass 2 (5%)
Bypass time, min 92 (89-95)
Aortic crossclamp time, min 46 (46)
Circulatory arrest time, min 15 (10-19)
BL, L 3.0 (0.4-30.0) 1.7 (0
ata are presented as the number of patients (%) or the mean value (ra
lcohol angioembolization; NSS, nephron-sparing surgery; IVC, inferior v
rrest; EBL, estimated blood loss.ade to bluntly dissect the thrombus free of the caval wall. l
292 The Journal of Thoracic and Cardiovascular Surgery ● Junn the few cases in which small parts of thrombus were
ttached to the caval wall, the small part of the IVC wall that
ad adherent thrombus, when safe, was removed. Although
egative surgical margins of the primary tumor were re-
orted in all patients (100%) in this group, the caval portion
f the venous tumor thrombus was initially left intact in 2
atients: one because of extensive growth into the posterior
ody wall and liver and the other because of intraoperative
oagulopathy. After 6 months of systemic therapy, the latter
atient underwent successful vena caval thrombectomy in
ay 2005 and at last follow-up was disease free and clin-
cally well. Four (29%) patients were treated postoperatively
ith immunotherapy. Postoperative radiation was given to
(21%) patients in this group, and 2 (14%) patients were
reated with chemotherapy.
evel IV Thrombi
our patients had a thrombus that extended above the dia-
hragm, with or without extension into the right atrium. One
atient received preoperative renal artery alcohol angioem-
olization. A cardiothoracic surgeon assisted in all 4 pro-
edures (100%). Two patients required cardiopulmonary
ypass with circulatory arrest. Negative surgical margins of
he primary tumor were reported in all 4 patients (100%).
he caval tumor thrombus was left intact in 2 patients. In 1
atient nephrectomy was performed, but 2 large metastatic
Level II Level III Level IV
15 (34%) 14 (32%) 4 (9%)
7 (47%) 5 (36%) 1 (25%)
15 (100%) 14 (100%) 4 (25%)
0 0 0
14 (93%) 9 (64%) 3 (75%)
0 5 (36%) 1 (25%)
0 0 0
1 (7%) 0 0
5) 350 (185-590) 460 (300-700) 460 (395-570)
14 (93%) 10 (71%) 0
21 (3-37) 34 (20-69) —
0 3 (21%) 0
— 33 (23-41) —
— 67 (43-204) —
0 0 2 (50%)
— — 92 (89-95)
— — 46 (46)
— — 15 (10-19)
) 2.5 (0.5-16.5) 5.1 (0.8-30.0) 1.6 (1.2-1.8)
unless otherwise specified. Angioembolization, Preoperative renal artery
ava; Cardiopulmonary bypass, cardiopulmonary bypass with circulatoryl
vel I
5%)
0
1%)
%)
2%)
0
8%)
0
00-46
0
—
0
—
—
0
—
—
—
.4-4.5
nge)
ena cymph node packets were found intraoperatively that were
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A
CDdherent to the vena cava. These prevented complete tumor
hrombus extraction and caval reconstruction. This patient
eceived prolonged interferon therapy, remained free of
istal tumor progression, and underwent a second operation
n which necrotic retroperitoneal lymph nodes were re-
oved. He continued to take interferon  until associated
ardiomyopathy required discontinuation. At 46 months
ostoperatively, this patient was clinically well but showed
igns of tumor progression with an enlarged IVC thrombus
nd IVC occlusion. This demonstrates that patients are
iving longer, even with advanced disease. At the time of
ast follow-up, this patient was scheduled to resume immu-
otherapy. The second patient had extensive liver metasta-
es, which contraindicated thrombus removal. Only 1 (25%)
atient in this group received postoperative immunotherapy.
ostoperative Care
atients spent a median of 2.0  11.9 days (range, 0.5-71
ays) in the intensive care unit, and median total length of
tay was 8  11 days (range, 1-71 days).
istopathology
n gross and microscopic evaluation, 15 (34%) patients had
umors that were fully contained within the renal capsule.
he mean pathologic tumor size was 10.3  3.9 cm (range,
.7-20.0 cm). There were no patients with tumors of Fuhr-
an nuclear grade I, 17 (39%) with tumors of grade II, 17
39%) with tumors of grade III, and 10 (23%) with tumors
f grade IV. Thirty-six (82%) patients had tumors of the
lear cell type, 5 (11%) had tumors with a sarcomatoid
attern, 2 (5%) had tumors with a granular pattern, and 1
2%) had a tumor with a papillary component. See Ta
or TNM tumor staging profiles.
omplications and Survival
ineteen postoperative complications occurred in 14 (32%)
ABLE 3. TNM16 tumor staging profiles
Classification
T (tumor)
T3b 30 (68%)
T3c 6 (14%)
T4 8 (18%)
N (node)
Nx 6 (14%)
N0 30 (68%)
N1 5 (11%)
N2 3 (7%)
M (metastasis)
M0 35 (80%)
M1 9 (20%)
ata are presented as the number of patients (%).atients, including 1 (2%) perioperative death on the first w
The Journal of Thoracic3
ostoperative day caused by coagulopathy. The most com-
on intraoperative and postoperative complications were
rolonged ileus (n 5, 11%), deep venous thrombosis (n
, 7%), pleural effusion (n  2, 5%), and splenectomy (n 
, 5%).
The presence of a perioperative complication did not
orrelate with mean age (P .68), age subgroups (P .33),
ex (P  .51), smoking history (P  .20), preoperative
merican Society of Anesthesiologists class (P  .18),
reoperative renal artery alcohol angioembolization (P 
12), or mean duration of the operation (P .30). However,
atients requiring intraoperative cardiovascular procedures
ad greater complication rates than patients without (P 
02).
At the time of the last follow-up, 26 patients were alive,
nd 14 were reported deceased, with a mean follow-up time
f 26 months. The mean survival of patients was 63.5 9.5
onths (median, 64 months; range, 2-117 months; Figure 2).
he 1-, 2-, and 5-year survival rates were 78%, 69%, and
6%, respectively. These favorable results are among the
ighest long-term survival rates reported by any recent
omparable series (Table 4).7,12,18-21
No significant survival differences were observed re-
arding age subgroups (P  .93), preoperative renal artery
lcohol angioembolization (P  .99), tumor status (P 
55), the presence of lymph node metastasis (P  .30), or
he presence of distant metastasis (P  .85). Additionally,
here was no significant survival difference between the
atients with TNM stage III and stage IV disease (P  .96).
In univariate analysis, by using the logistic regression
odel, patients who required cardiovascular procedures (IVC
lamping, right heart venovenous bypass, or cardiopulmo-
ary bypass with circulatory arrest) had an approximately
-fold increased risk of complication (P  .11). In addition,
atients with level III and level IV thrombi had an approx-
mately 2-fold increased risk of complication versus patients
igure 2. Kaplan-Meier estimates of overall survival of patients
ith renal cell carcinoma with venous tumor thrombus.ith level I and II thrombi (P  .28).
and Cardiovascular Surgery ● Volume 131, Number 6 1293
D
U
t s
c
l
p
r
t
a
m
d
t
r at
c
t
s
m
u
w
1
1
a
c
a
i
g
t
o es
e ival.
H
a
g
t
t
p
t
s
l ode
m
r
a
o
t
a
c
s
d
t
c
t
t
e
W
l
e
o
c
a
c
i
t
i
m
s
i
s
c
i
h
t
p
T
S
B
G
J
N
S
T
C
A
I ortal
Surgery for Acquired Cardiovascular Disease Lubahn et al
1
A
CDiscussion
p to 20% of patients with RCC have tumor extension into
he venous system on presentation.7-12 The tumor thrombu
an extend into the renal vein (level I), the IVC below the
iver (level II), the IVC behind the liver and up to the dia-
hragm (level III), and above the diaphragm and into the
ight atrium (level IV). It has even been reported that
umor thrombi can extend as far cephalad as the pulmonary
rtery.13
Considerable advances have been made in the manage-
ent of a tumor thrombus. These include the use of new
iagnostic imaging modalities to define its level, as well as
he use of extracorporeal bypass to permit safe surgical
esection.12 Additionally, several studies demonstrate th
ombined aggressive surgical intervention and postopera-
ive immunotherapy have a positive influence on long-term
urvival in patients with conventional (clear cell) RCC, the
ost prevalent subtype.22-25
Preoperative renal artery alcohol angioembolization was
sed more frequently in the most recent cases of this series,
ith 85% (n  11) of the procedures performed in the last
5 months of data collection. We performed this procedure
day before surgical intervention to diminish intraoper-
tive bleeding. Several disadvantages of this procedure in-
lude the cost of the procedure, the extra day in the hospital,
nd morbidity, such as flank pain and toxicity from renal
nfarction.
Although higher levels of tumor thrombi constitute
reater surgical difficulty and risk, the stage of the primary
umor and lymph node status remain the main determinants
f prognosis.7,9,11,14,21 There is no evidence that the pr-
nce of tumor thrombus alone is a detriment to surv8
owever, untreated venous tumor thrombi might result in
cute pulmonary emboli with sudden fatal outcomes. Ag-
ressive resection of the primary tumor and associated
umor thrombus offers the highest patient survival.
In a recent series Sweeney and associates12 reported that
here was a significant decrease in long-term survival in
ABLE 4. Complication and survival rates in recent series
eries Patients 5-y survival
lute and coworkers18 540 44.4% 
oetzl and coworkers19 56 4% 
ibiki and coworkers20 31 42% 
esbitt and coworkers7 37 33.6% 
weeney and coworkers12 96 35% 
suji and coworkers21 33 44% 
urrent series 44 56%
ll series include patients with preoperative metastatic disease. Patients, N
ntraoperative, intraoperative mortality rate; Perioperative, perioperative matients with lymph node metastases. On the other hand, r
294 The Journal of Thoracic and Cardiovascular Surgery ● Junhey did not observe a statistically significant difference in
urvival on the basis of distant metastasis. Tsuji and col-
eagues21 reported similar results according to lymph n
etastasis and distant metastasis. Findings from our series
egarding the effect of each of these factors (lymph node
nd metastasis status) were consistent with these reports, but
ur data regarding lymph node status did not reach statis-
ical significance because of limitations in sample size.
Radical nephrectomy and tumor thrombectomy require
dequate control of bleeding. This was achievable in most
ases with control of the renal vein and IVC alone, but
pecific intraoperative cardiovascular procedures were used
epending on the cephalad extent of the thrombus. Nephrec-
omy was performed without any additional vascular pro-
edures in patients with level I thrombi. When the tumor
hrombus was localized within the infrahepatic IVC, extrac-
ion was usually achieved by means of IVC clamping. Caval
xposure might or might not have required sternotomy.
hen the tumor thrombus extended into the IVC behind the
iver or higher, exposure and isolation of the IVC were more
xtensive. That often required mobilization of the liver with
r without the use of right heart venovenous bypass or
ardiopulmonary bypass and deep hypothermic circulatory
rrest. Right heart venovenous bypass added a measure of
ardiac stability in hemodynamically unstable patients dur-
ng caval clamping. Cardiopulmonary bypass with circula-
ory arrest was reserved for patients with the most extensive
ntracardiac thrombi. Cardiothoracic surgeons offered the
ost complete range of operative techniques that were neces-
ary depending on the full extent of the intraoperative find-
ngs or when the patient response to IVC clamping required
ternotomy, right heart venovenous bypass, or complete
ardiopulmonary bypass with circulatory arrest. However,
n many cases a liver transplant or vascular surgeon could
ave provided the requisite skills for caval thrombectomy.
Nineteen postoperative complications occurred in 14 pa-
ients, but there were no intraoperative deaths. Only 1 (2%)
erioperative death occurred. The 1-, 2-, and 5-year survival
Comp
Deaths
YearsIntraoperative Perioperative
11% 1.3% 1.9% 1970-2000
14% 0 1.8% 1989-2003
35% 3.2% 0 1980-2001
30% 0 2.7% 1989-1996
38% 0 5.2% 1985-2001
— 0 6.1% 1983-1999
32% 0 2.3% 1991-2005
r of patients in statistical analyses; Comp, perioperative complication rate;
ity rate; —, data not reported.umbeates were 78%, 69%, and 56%, respectively. These favor-
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A
CDble results are among the highest survival rates in compa-
able recent series and can be attributed to the aggressive
reatment strategy taken with careful attention to vascular
ontrol (Table 4).
Radical nephrectomy and thrombectomy offers an effec-
ive option for patients with kidney tumors and tumor
hrombi. Despite the increased risk of perioperative com-
lications associated with the use of cardiovascular proce-
ures, an aggressive approach does not negatively affect
ong-term survival, even in the presence of metastatic dis-
ase. A multidisciplinary approach, including urology, in-
erventional radiology, and cardiothoracic surgery, provides
ptimal results.
The conclusions are limited by several characteristics of
his study. These include the retrospective and uncontrolled
ature of this series, that it is based on a single institution’s
xperience, and the relatively small sample size of the
tudied patient population. Despite these reservations, this
eport is based on enough patients to provide an adequate
onclusion and represents our ongoing cumulative experi-
nce with an increasing rate of referral of patients with this
urgically challenging disease.
We thank Jesse Williams and Connie Smith for their assistance
ith patient follow-up and medical record data collection.
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